Frontiers in Immunology · 2023 · 23 citations · 89 references
Life SciencesCell BiologyPathobiologyCell SignalingImmunopathologyInflammationGastrointestinal InflammationGastrointestinal PathophysiologyInflammatory Bowel DiseaseMitochondrial DysfunctionMucosal InflammationNicotinamide Adenine Dinucleotide MetabolismInflammatory Bowel Disease PathogenesisInflammatory Bowel Disease PathophysiologyNad+ Biosynthetic EnzymesNad+-consuming ReactionsNad+-dependent EnzymesNicotinamide Adenine Dinucleotide BiosynthesisPeroxisome Proliferator-activated Receptor Gamma Coactivator 1-Alpha RegulationPeroxisome Proliferator-activated Receptor Gamma Coactivator 1-Alpha Signaling
Introduction: We have previously demonstrated that a pathologic downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1α) within the intestinal epithelium contributes to the pathogenesis of inflammatory bowel disease (IBD). However, the mechanism underlying downregulation of PGC1α expression and activity during IBD is not yet clear. Methods: ) were subjected to experimental colitis and treated with nicotinamide riboside. Western blot, high-resolution respirometry, nicotinamide adenine dinucleotide (NAD+) quantification, and immunoprecipitation were used to in this study. Results: We demonstrate a significant depletion in the NAD+ levels within the intestinal epithelium of mice undergoing experimental colitis, as well as humans with ulcerative colitis. While we found no decrease in the levels of NAD+-synthesizing enzymes within the intestinal epithelium of mice undergoing experimental colitis, we did find an increase in the mRNA level, as well as the enzymatic activity, of the NAD+-consuming enzyme poly(ADP-ribose) polymerase-1 (PARP1). Treatment of mice undergoing experimental colitis with an NAD+ precursor reduced the severity of colitis, restored mitochondrial function, and increased active PGC1α levels; however, NAD+ repletion did not benefit transgenic mice that lack PGC1α within the intestinal epithelium, suggesting that the therapeutic effects require an intact PGC1α axis. Discussion: Our results emphasize the importance of PGC1α expression to both mitochondrial health and homeostasis within the intestinal epithelium and suggest a novel therapeutic approach for disease management. These findings also provide a mechanistic basis for clinical trials of nicotinamide riboside in IBD patients.
89
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Joseph T. Rodgers, Carles Lerín, Wilhelm Haas et al. · Nature · 2005 · 3.1K citations
Hongbo Zhang, Dongryeol Ryu, Yibo Wu et al. · Science · 2016 · 1.2K citations · Full text
Daniel Berg, N Davidson, Ralf Kühn et al. · Journal of Clinical Investigation · 1996 · 1.1K citations · Full text